Leveraging technology to advance clinical research
As a certified partner, Linical will leverage Science 37’s Metasite™ to provide global access to patients beyond its existing brick-and-mortar site network.
RESEARCH TRIANGLE PARK, N.C. and OSAKA, JAPAN, November 17, 2022—Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, and Linical Americas, a U.S. subsidiary of The Linical Group, a leading global contract research organization (CRO), today announced a partnership that will facilitate the deployment of decentralized clinical trial solutions--powered by Science 37—to Linical’s international clients, enabling patient access from virtually anywhere. As part of the collaboration, Linical will integrate Science 37’s virtual site capabilities into its network, to deliver faster, more inclusive, patient-centric trials to global research clients. The partnership will enable decentralized and hybrid trials, focusing on treatments in the oncology, central nervous system, and infectious disease therapeutic areas.
“By partnering with Linical, we have an important new ally in our mission to accelerate clinical research and enable universal access for patients. Our technology-enabled Metasite will empower and enhance Linical’s solutions, helping patients access new life-changing treatments quicker, in the largest and most prevalent therapeutic areas.”
David ComanChief Executive Officer of Science 37
Linical is a mid-size CRO headquartered in Osaka, Japan, with offices in multiple locations across North America, Europe, and Asia. By focusing on three major therapeutic areas—oncology, CNS, and infectious disease—Linical can deliver “the right size, right reach, and right team” from early-stage trials to large, multinational studies.
“We are delighted to become a certified partner with Science 37, and we look forward to providing our global clients with the numerous proven benefits of decentralized and hybrid trials enabled by Science 37,” said Vita Lanoce, MS, Chief Executive Officer of Linical Americas. “Science 37’s deep expertise and experience in oncology, CNS, and infectious disease align very much with our own. We look forward to working with them to help our global clients accelerate research, enable universal access, and reduce the patient burden in these important therapeutic areas.” As a certified partner, Linical will leverage Science 37’s Metasite™ to provide global access to patients beyond its existing brick-and-mortar site network. Linical Americas, a global Contract Research Organization (CRO) for full-service drug development, announced Clareece West has joined as Executive Vice President of Commercial Operations. Ms. West will lead the organization’s sales, marketing, and proposals groups to drive growth in market share, expand strategic partnerships, and spearhead the integrated commercial success of the organization.
About Science 37
Science 37, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical research by enabling universal access for patients. In 2014, we pioneered decentralized clinical trials, and we continue to lead, delivering faster, more inclusive, patient-centric trials, by removing barriers to access through a tech-enabled virtual site. The Science 37 Metasite™ leverages a unified set of people, processes, and technology, delivering greater consistency and regulatory-quality data. With the most medical and operational experience across therapeutic areas, Science 37 has enabled up to 21x faster enrollment, 28% better retention, and 3x more diversity vs. the traditional site. To learn more, visit www.science37.com, or email science37@science37.com.
About Linical
Linical is a public, mid-sized Contract Research Organization headquartered in Japan with a significant presence across North America, Europe, and Asia-Pacific. Linical provides the full spectrum of drug development services from early stage to large-scale, multinational studies. Our areas of focus include Phase I-IV studies in oncology, infectious disease, and CNS. Rather than be all things to the market, this intentional design allows us to provide our clients the right size, right reach, and right team.
Cautionary Note Regarding Forward-Looking Statements:
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the products offered by Science 37, its sales pipeline and the markets in which it operates. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the ability to maintain the listing of Science 37’s securities on Nasdaq, (ii) volatility in the price of Science 37’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Science 37 operates, variations in performance across competitors, changes in laws and regulations affecting Science 37’s business and changes in its capital structure, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional opportunities, (iv) the risk that Science 37 may never achieve or sustain profitability, (v) the risk that Science 37 will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all, (vi) failure to realize anticipated cost savings, and (vii) the potential adverse effects of the ongoing global COVID-19 pandemic. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 22, 2022 and in our other documents filed by Science 37 from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Science 37 assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Science 37 does not give any assurance that Science 37 will achieve its expectations.
Media Inquiries:
Grazia Mohren
Science 37
PR@science37.com
Alison Cundari
Linical
acundari@linicalamericas.com
Investor Relations:
Steve HalperLifeSci Advisors
Investors@science37.com